Heavy Chain Anti-CD19 Antibodies for Stable High-Affinity Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing monoclonal antibodies and treatments targeting CD19 for B-cell disorders face challenges in specificity and efficacy, particularly in conditions like diffuse large B cell lymphoma, acute lymphoblastic leukemia, non-Hodgkin's lymphoma, systemic lupus erythematosus, and rheumatoid arthritis, due to limitations in antigen-binding affinity and stability.
Innovation Solution
Development of heavy chain-only antibodies, known as UniAbs, with specific CDR sequences and frameworks for high affinity binding to CD19, including multi-specific and bispecific variants, which can be administered in pharmaceutical compositions for targeted treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional monoclonal antibodies are used to target CD19, then they can recognize and bind to the antigen, but they exhibit limitations in antigen-binding affinity and stability
Solution Approach 1:
The patent extracts and utilizes only the heavy chain portion of the antibody (VHH domain) while removing the light chain, creating heavy chain-only antibodies that maintain antigen-binding capability with improved stability and affinity for CD19 target
Solution Approach 2:
The patent modifies the antibody structure by changing from conventional IgG format to heavy chain-only format, altering the molecular parameters such as size, stability, and binding kinetics to achieve superior antigen-binding characteristics
2Reliability
If conventional antibodies with light chains are used, then they provide structural stability, but they have reduced specificity and efficacy in targeting CD19-expressing cells
Solution Approach 1:
The patent removes the light chain component from the conventional antibody structure, retaining only the heavy chain (VHH-CH2-CH3) to simplify the molecular architecture while enhancing targeting specificity and reducing structural complexity
Solution Approach 2:
The patent segments the antibody into distinct functional modules (VHH for antigen binding, CH2-CH3 for structural stability and effector functions), allowing optimization of each segment's contribution to overall performance
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The UniAbs demonstrate enhanced antigen-binding specificity and stability, effectively reducing tumor burden and cytotoxicity, and are suitable for treating B-cell disorders by targeting CD19-expressing cells.
Implementation Method 1
a heavy chain variable region that binds to human CD19
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Anti-CD19 heavy chain antibodies (e.g., UniAbs™) are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B cell disorders that are characterized by the expression of CD19.